Using the INSIGHT© tool below, users can generate a predicted response and an individualized hazard ratio for the effects of canagliflozin therapy on major adverse cardiac events by entering select patient characteristics and labs. A detailed description of the development and validation of this tool are presented in the work by Evangelos K. Oikonomou, et al in Diabetes Care. This tool is for demonstration only and is not intended for clinical use. If you have any questions or feedback regarding the tool, please contact us at cards@yale.edu.